Quick results achieved with the Adtec SteriPlas

How often do LVAD patients with infection need treatment with the Adtec SteriPlas?


We recommend a minimum treatment of twice per week. This applies to both outpatients in day clinics and inpatients who have been admitted into the wards.


The treatment time itself is as quick as 3 minutes. During these short minutes, the components of cold plasma quickly bombard the cellular structure of bacteria to create micropores which allows access to the microbial DNA for total destruction. This applies to all forms of bacteria regardless of their resistance profile or if they are protected within biofilm.


How quick have patients with LVAD infections healed?


Our clinical evidence has shown patients have healed in as quick of two weeks of treatment. These are patients who have failed previous therapeutic attempts with conventional treatment methods.

Promising, consistent and reliable results achieved with the Adtec SteriPlas


Whilst Left ventricular assist devices (LVADs) have become essential mechanical pumps for patients who have had end stage heart failures, they are also prone to infections especially with the presence of biofilm that complicates treatment options. Cardiologists often rely on conventional antibiotic therapy but with rising antimicrobial resistance rates, they sometimes offer little to no help in achieving stabilisation.

The strong properties of the Adtec SteriPlas cold plasma has been proven to offer complete stabilisation of the LVAD system by destroying all forms of multi-resistant bacteria present, even if they are protected within biofilm. This is due to the unique cold plasma properties that can travel through the gaps around and down the driveline to reach the site of biofilm. This area would normally have been difficult to treat with conventional therapies such as antimicrobial dressings as they are hard to reach, but the Adtec SteriPlas has shown to travel to these sites with ease due to its remarkable antibacterial gaseous properties.


To learn more about our strong collection of clinical evidence, please contact us at info@adtecplasma.com to learn more

We welcome you to our new office

We are excited to introduce you to our new office layout. The renovation works have finally been completed at our new location and all of our staff are now back onsite to continue business as normal. We look forward to welcoming our customers and partners to our new office, as well as to meet you all soon at the upcoming exhibitions and customer meetings we have planned.



Seasons Greetings

This holiday season is unlike any other, to cap off a year unlike any other. As we welcome 2021, we wish you a better year with moments of peace, joy and success. Thank you for your continued support and business.

Sending you the warmest greetings and warmest wishes this holiday season from all at Adtec Healthcare.

Accounts review for 2020

Adtec Healthcare is the European subsidiary for Adtec Plasma Technology in Japan. Our parent company is a renowned public company listed on the Tokyo Stock Exchange Market. As part of our annual accounts review, the reports are published on our websites: https://www.adtec-rf.co.jp/ir-news/1485/


Given the challenging year of 2020, we are grateful to announce a revenue of £52 million and net profit of £6.5 million. Our forecast revenue for 2021 is £55 million with a net profit £6.7 million. We are thankful to our faithful employees, customers and suppliers for their ongoing support much of which would not have been possible without their existence.


As part of the Adtec promise, we pledge to face the future with confidence, continue working to high quality standards and to continue our support to other businesses during the challenging times ahead.